{"contentid": 488135, "importid": NaN, "name": "XOMA buys future milestones and royalties from Viracta", "introduction": "XOMA Corp has purchased the potential future milestones and royalties associated with existing licenses relating to two clinical-stage drug candidates that were obtained in Viracta Therapeutics\u00e2\u0080\u0099 merger with US drug developer Sunesis Pharmaceuticals.", "content": "<p>XOMA Corp (Nasdaq: XOMA) has purchased the potential future milestones and royalties associated with existing licenses relating to two clinical-stage drug candidates that were obtained in Viracta Therapeutics&rsquo; (Nasdaq: VIRX) merger with US drug developer Sunesis Pharmaceuticals.</p>\n<p>Viracta, whose shares dipped 5% to $8.21 on the news yesterday, will receive an upfront payment of $13.5 million and up to $20 million in a pre-commercialization, event-based milestone.&nbsp;</p>\n<p>The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, which recently initiated a pivotal Phase II with DAY101 in pediatric low-grade glioma. The second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma as a potential treatment for acute myeloid leukemia.&nbsp;&nbsp;<strong>&nbsp;</strong></p>\n<p>&ldquo;This transaction with XOMA offered a unique opportunity for Viracta to secure meaningful non-dilutive capital and further strengthen our balance sheet prior to the initiation of our registration trial for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoma and our Phase Ib/II trial in EBV-positive solid tumors,&rdquo; said Dan Chevallard, chief operating officer and chief financial officer of Viracta, adding: &ldquo;We look forward to evaluating opportunities to strategically deploy this capital to further develop, expand and diversify our portfolio and pipeline.&rdquo;&nbsp;</p>\n<p>&ldquo;XOMA&rsquo;s purpose-built milestone and royalty acquisition-focused business provides an alternative source of capital and offers an ideal solution for companies like Viracta to capitalize on the opportunity to divest non-strategic assets,&rdquo; commented Jim Neal, chief executive of XOMA. &ldquo;We like both Day One and Denovo&rsquo;s thoughtful clinical development approaches, and we look forward to seeing them progress,&rdquo; he noted. &nbsp;</p>\n<p>Under the terms of the agreement, XOMA has acquired potential royalty economics related to DAY101 and up to $54 million in pre-commercialization, event-based milestones and high single-digit net royalties on sales related to vosaroxin and up to $57 million in regulatory and commercial milestones.&nbsp;&nbsp;&nbsp;</p>", "date": "2021-03-24 10:55:00", "meta_title": "XOMA buys future milestones and royalties from Viracta", "meta_keywords": "XOMA Corp, Viracta Therapeutics, Milestones, Royalties, DAY101, Vosaroxin, Sunesis", "meta_description": "XOMA buys future milestones and royalties from Viracta", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-24 10:54:26", "updated": "2021-03-24 11:01:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/xoma-buys-future-milestones-and-royalties-from-viracta", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "xoma_large.png", "image2id": "xoma_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Oncology", "topic_tag": "Deals", "geography_tag": "USA", "company_tag": "Viracta Therapeutics, XOMA Corp", "drug_tag": "DAY101, vosaroxin", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-24 10:55:00"}